In this issue of PET Clinics, guest editors Drs. Frederik Giesel, Rodney Hicks, and Ken Herrmann bring their considerable expertise to the topic of Fibroblast Activation Protein Imaging. Fibroblast activation protein (FAP) represents one of the most exciting pan-cancer targets identified in recent decades and has generated both active research and rapid clinical adoption of diagnostic agents based on small molecule FAP inhibitor (FAPI) molecules. In this issue, top experts who have been actively involved in developing or researching the utility of these agents across a broad spectrum of diseases summarize the current evidence regarding clinical applications of FAP-based imaging probes for diagnosis and, potentially, also for therapy.

• Contains 16 practice-oriented topics including fibroblast activation protein inhibitor (FAPI) PET imaging in pancreatic cancer; fibroblast activation protein inhibitor (FAPI) PET imaging in colorectal cancer; fibroblast activation protein inhibitor (FAPI) cardiac imaging; fibroblast activation protein inhibitor (FAPI) PET/CT in gastric cancer; and more.

• Provides in-depth clinical reviews on fibroblast activation protein imaging, offering actionable insights for clinical practice.

• Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.